Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian's perspective.

Bayoumy, A B; de Boer, N K H; Ansari, A R; Crouwel, F; Mulder, C J J

Bayoumy, A B; de Boer, N K H; Ansari, A R; Crouwel, F; Mulder, C J J.

Afiliação

Bayoumy AB; Faculty of Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
de Boer NKH; Department of Gastroenterology and Hepatology, Amsterdam UMC, VU University Medical Center, AG&M Research Institute, Amsterdam, The Netherlands.
Ansari AR; Department of Gastroenterology, East Surrey Hospital, Surrey, UK.
Crouwel F; Department of Gastroenterology and Hepatology, Amsterdam UMC, VU University Medical Center, AG&M Research Institute, Amsterdam, The Netherlands.
Mulder CJJ; Department of Gastroenterology and Hepatology, Amsterdam UMC, VU University Medical Center, AG&M Research Institute, Amsterdam, The Netherlands.

J Pharm Policy Pract ; 13: 45, 2020.

Article em En | MEDLINE | ID: mdl-32695427

Palavras-chave

COVID-19; Centralized procedure (CP); Chenodeoxycholic acid; Decentralized procedure (DCP); Drug rediscovery; Drug repositioning; Hydroxychloroquine; Magistral compounding; Market Authorization Application (MAA); Mexiletine; Mutual recognition procedure (MRP); Orphan drugs; Pharmaceutical compounding; Reference Member State (RMS); Remdesivir; SARS-COV 2; Thalidomide; Thioguanine

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Pharm Policy Pract Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda